Title:
CROSS-SPECIES ANTI-LATENT TGF-β1 ANTIBODIES AND METHODS OF USE
Document Type and Number:
Japanese Patent JP2021036864
Kind Code:
A
Abstract:
To provide cross-species anti-latent TGF-β1 antibodies which inhibit protease-mediated activation of latent TGF-β1 without inhibiting integrin mediated activation of latent TGF-β1.SOLUTION: In order to obtain anti-latent TGF-β1 antibodies of the invention, anti-latent TGF-β1 antibodies which inhibit protease-mediated activation of latent TGF-β1 without inhibiting integrin-mediated activation of latent TGF-β1 are screened, and then humanized, and further optimized. The invention also provides combination therapies comprising an anti-latent TGF-β1 antibody and one or more immune checkpoint inhibitors, preferably PD-1 binding antagonists.SELECTED DRAWING: None
More Like This:
| JP2024517907 | antigen binding molecule |
| WO/2023/001258 | PHARMACEUTICAL USE OF ANTI-TUMOR INHIBIN 2 ANTIBODY |
| WO/2012/137993 | ANTIBODIES AGAINST ANGIOPOIETINS 1 AND 2, AND THEIR USE |
Inventors:
SHIMADA HIDEKI
KANAMORI MASAKAZU
XING'ER CHRISTINE KOO
KANAMORI MASAKAZU
XING'ER CHRISTINE KOO
Application Number:
JP2020144024A
Publication Date:
March 11, 2021
Filing Date:
August 28, 2020
Export Citation:
Assignee:
CHUGAI PHARMACEUTICAL CO LTD
International Classes:
C12N15/13; A61K39/395; A61K45/00; A61K47/68; A61P35/00; A61P43/00; C07K16/22; C07K16/46; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/63; C12P21/08
Foreign References:
| WO2018043734A1 | 2018-03-08 | |||
| WO2017156500A1 | 2017-09-14 | |||
| WO2019163927A1 | 2019-08-29 | |||
| WO2019045086A1 | 2019-03-07 |
Attorney, Agent or Firm:
Masao Haruna
Hatsushi Shimizu
Hirotaka Yamaguchi
Toshi Gobe
Ryuichi Inoue
Toshimitsu Sato
Koichi Niimi
Tomohiko Kobayashi
Hideki Kodera
Masato Ozeki
Yoshihiro Igarashi
Kazuya Kawamoto
Hatsushi Shimizu
Hirotaka Yamaguchi
Toshi Gobe
Ryuichi Inoue
Toshimitsu Sato
Koichi Niimi
Tomohiko Kobayashi
Hideki Kodera
Masato Ozeki
Yoshihiro Igarashi
Kazuya Kawamoto